Migraine
Conditions
Brief summary
This study aims to investigate whether the functional alterations in the brain of individuals with migraine appear before the peripheral vascular changes. This will be investigated using functional and structural neuroimaging in individuals with spontaneous menstually-related migraine.
Detailed description
Spontaneous migraine attacks are unpredictable and therefore been logistically arduous to investigate in neuroimaging studies. Menstrually-related migraine provides an opportunity to study spontaneous attacks in a controlled imaging setup. The present project aims to investigate women with menstrually-related migraine using daily functional magnetic resonance imaging (MRI) scans 2-3 days before the onset of the menstrual bleeding and until (and including) the headache phase of migraine or up to five consecutive days. A control-group of women without migraine will also be recruited and undergo the same MRI scan protocol.
Interventions
None listed
Sponsors
Danish Headache Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
For women with migraine \- Episodic menstrually-related migraine without aura \> 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria For women with migraine and healthy women * 18-40 years of age * Weight 50-100 kg * Regular menstruation
Exclusion criteria
For women with migraine * Other primary headache disorders than migraine, except infrequent episodic tension-type headache according to the ICHD-3 criteria * Secondary headache disorders * Headache on the first scan day or 48 hours before the first scan * Absence of the menstruation for the past 12 months * Daily intake of medication of any kind except oral contraceptives * Ingestion of any type of medication later than 4 times the plasma half-life of the substance in question (on the day of the scan), except for oral contraceptives * Intake of coffee, tea or alcohol 12 hours prior to scan days * Fertile women not using safe contraception. Fertile women are defined as women without hysterectomy and \< 2 years postmenopausal women. Safe contraception includes the intrauterine device, oral contraceptive pills, surgical sterilization of the woman, depot progestogen or condoms * Change of hormonal contraceptives for the past 3 months * Perimenstrual syndrome * Pregnant or breastfeeding women * Information or clinical signs of: * Hypertension (systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 100 mm Hg) * Low blood pressure (systolic blood pressure \< 100 mm Hg and/or diastolic blood pressure \< 50 mm Hg) * Cardiovascular diseases of any kind, including cerebrovascular disease * Diabetes * Unregulated mental illness or substance abuse * Illnesses of any kind deemed incompatible by the examining physician for participation in the study * Contraindications to MRI (including metal in the body or claustrophobia) * Do not want to be informed about unexpected pathological findings on the MRI For healthy women * History of any primary headache except infrequent episodic tension-type headache according to the ICHD-3 criteria * First degree family history of primary headache disorders except infrequent episodic tension-type headache according to the ICHD-3 criteria (max five days/month) * Secondary headache disorders * Headache during the menstrual period from 2 days before to 2 days after the first menstrual bleeding day * Headache on the first scan day or 48 hours before the first scan * Absence of the menstruation for the past 12 months * Daily intake of medication of any kind except oral contraceptives * Ingestion of any type of medication later than 4 times the plasma half-life of the substance in question (on the day of the scan), except for oral contraceptives * Intake of coffee, tea or alcohol 12 hours prior to scan days * Fertile women not using safe contraception. Fertile women are defined as women without hysterectomy and \< 2 years postmenopausal women. Safe contraception includes the intrauterine device, oral contraceptive pills, surgical sterilization of the woman, depot progestogen or condoms * Change of hormonal contraceptives for the past 3 months * Pregnant or breastfeeding women * Perimenstrual syndrome * Information or clinical signs of: * Hypertension (systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 100 mm Hg) * Low blood pressure (systolic blood pressure \<100 mm Hg and/or diastolic blood pressure \< 50 mm Hg) Investigation of functional brain features in women with migraine * Cardiovascular diseases of any kind, including cerebrovascular disease. * Diabetes * Unregulated mental illness or substance abuse * Illnesses of any kind deemed incompatible by the examining physician for participation in the study * Contraindications to MRI (including metal in the body or claustrophobia) * Do not want to be informed about unexpected pathological findings on the MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arterial circumference in healthy volunteers | Up to 5 days in relation to menstruation | Changes in arterial circumference during the menstrual period in healthy volunteers. This will assessed using Magnetic Resonance Angiography. |
| Arterial circumference in migraine patients | Up to 5 days in relation to menstruation | Changes in arterial circumference during the menstrual period. This will assessed using Magnetic Resonance Angiography. |
| Arterial circumference after rescue medication in migraine patients | Up to 5 days in relation to menstruation | Changes in arterial circumference after rescue medication in migraine patients. This will assessed using Magnetic Resonance Angiography. |
| Brain excitability in healthy volunteers | Up to 5 days in relation to menstruation | Changes in brain excitability or connectivity in areas related to migraine during the menstrual period in healthy volunteers. This will be assessed using functional magnetic resonance imaging. |
| Brain connectivity in healthy volunteers | Up to 5 days in relation to menstruation | Changes in brain connectivity in areas related to migraine during the menstrual period in healthy volunteers. This will be assessed using functional magnetic resonance imaging. |
| Brain excitability in migraine patients | Up to 5 days in relation to menstruation | Changes in the migraine brain excitability in areas related to migraine during the menstrual period. This will be assessed functional magnetic resonance imaging. |
| Brain connectivity in migraine patients | Up to 5 days in relation to menstruation | Changes in the migraine brain connectivity in areas related to migraine during the menstrual period. This will be assessed functional magnetic resonance imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association of the migraine attack features to brain excitability | Up to 5 days in relation to menstruation | Investigate the association of the migraine attack features to alterations in the brain excitability during the menstrual period. Functional magnetic resonance imaging and headache questionnaire will be used. |
| Association of the migraine attack features to functional connectivity | Up to 5 days in relation to menstruation | Investigate the association of the migraine attack features to alterations in the brain functional connectivity during the menstrual period. Functional magnetic resonance imaging and headache questionnaire will be used. |
| Association of the migraine attack features to vasculature changes | Up to 5 days in relation to menstruation | Investigate the association of the migraine attack features to alterations in the arterial circumference. Magnetic Resonance Angiography and headache questionnaire will be used. |
| Migraine attacks during the menstrual period | Up to 7 days in relation to menstruation | Investigate features of migraine attacks during the menstrual period using a headache questionnaire |
Countries
Denmark
Contacts
Primary ContactFaisal Mohammad Amin
Outcome results
None listed